Biocon Receives US FDA Approval for Pebrilzo Breast Cancer Biosimilar
Biocon receives U.S. FDA approval for Pebrilzo, its fifth oncology biosimilar. The company secured a Q3 2028 U.S. launch via a settlement with Genentech.
ALFA News
Straight from the exchange filing
Latest Biocon Ltd stock news from NSE and BSE filings, 3 stories so far.
Biocon receives U.S. FDA approval for Pebrilzo, its fifth oncology biosimilar. The company secured a Q3 2028 U.S. launch via a settlement with Genentech.